Legal & General Group Plc Acquires New Position in Smith & Nephew SNATS, Inc. $SNN

Legal & General Group Plc acquired a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 563,432 shares of the medical equipment provider’s stock, valued at approximately $35,338,000. Legal & General Group Plc owned 0.13% of Smith & Nephew SNATS as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SNN. Clearstead Trust LLC bought a new position in Smith & Nephew SNATS during the 2nd quarter worth $25,000. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS in the fourth quarter valued at $27,000. Arax Advisory Partners lifted its stake in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter valued at $36,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Smith & Nephew SNATS during the third quarter valued at $41,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Down 0.4%

SNN stock opened at $29.01 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. Smith & Nephew SNATS, Inc. has a 12 month low of $28.56 and a 12 month high of $38.79. The firm has a 50 day moving average of $30.22 and a two-hundred day moving average of $31.68.

Smith & Nephew SNATS Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a dividend yield of 205.0%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SNN. Wall Street Zen raised Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Monday, August 24th. Canaccord Genuity Group lowered their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. Zacks Research downgraded shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Finally, Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.